Revolution Medicines (NASDAQ:RVMD) Posts Quarterly Earnings Results, Misses Estimates By $0.30 EPS

Revolution Medicines (NASDAQ:RVMD) issued its quarterly earnings data on Wednesday. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30), FiscalAI reports. During the same quarter in the prior year, the company posted ($1.12) EPS.

Here are the key takeaways from Revolution Medicines’ conference call:

• daraxonrasib registrational enrollment for RASolute‑302 is complete and an OS event‑driven top‑line readout is expected in the first half of 2026, potentially a major value inflection if positive.
• Zoldonrasib showed encouraging first‑line PDAC combo activity (63% partial response, 95% disease control rate in early data), and the company has initiated RESOLUTE‑305 with RASolute‑309 planned for H2 2026.
• RevMed now has a broad RAS(ON) portfolio — four clinical‑stage inhibitors (daraxonrasib, elironrasib, zoldonrasib, RMC‑5127), a preclinical resistance‑targeting class (RMC‑055) slated for clinical development, and >2,500 patients dosed across programs with eight ongoing/planned Phase III trials.
• Strong liquidity position with $2.03 billion in cash and investments and an innovative Royalty Pharma arrangement providing up to $2 billion in committed capital (first $250M tranche received), reducing near‑term financing risk.
• Spending is ramping materially: Q4 net loss was $364.9M and RevMed guided full‑year 2026 GAAP operating expenses of $1.6–$1.7 billion (including $180–$200M stock‑based comp), reflecting significantly higher R&D and commercial preparation costs that will increase near‑term cash burn.

Revolution Medicines Stock Down 1.5%

Shares of NASDAQ:RVMD traded down $1.59 during mid-day trading on Wednesday, reaching $103.24. 2,763,239 shares of the company traded hands, compared to its average volume of 1,895,848. The company’s 50 day moving average price is $97.66 and its 200-day moving average price is $69.42. Revolution Medicines has a 52 week low of $29.17 and a 52 week high of $124.49. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16.

Insider Activity

In other Revolution Medicines news, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $98.00, for a total transaction of $980,000.00. Following the transaction, the chief financial officer owned 108,065 shares of the company’s stock, valued at $10,590,370. The trade was a 8.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark A. Goldsmith sold 15,394 shares of Revolution Medicines stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $1,182,567.08. Following the transaction, the insider owned 232,469 shares in the company, valued at approximately $17,858,268.58. This trade represents a 6.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 113,792 shares of company stock worth $10,734,640 in the last quarter. 8.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Revolution Medicines

A number of hedge funds have recently made changes to their positions in the business. Nextech Invest Ltd. raised its stake in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the period. Millennium Management LLC raised its position in shares of Revolution Medicines by 681.8% during the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after buying an additional 136,353 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares in the last quarter. Invesco Ltd. boosted its position in shares of Revolution Medicines by 19.3% during the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after acquiring an additional 36,760 shares during the last quarter. Finally, Jump Financial LLC boosted its position in shares of Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after acquiring an additional 7,137 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RVMD. JPMorgan Chase & Co. increased their price target on Revolution Medicines from $71.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Wolfe Research started coverage on Revolution Medicines in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price objective for the company. Royal Bank Of Canada started coverage on Revolution Medicines in a research note on Monday, November 3rd. They set an “outperform” rating and a $77.00 price target for the company. Needham & Company LLC upped their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, UBS Group upgraded shares of Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.